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Background: Classic Ehlers–Danlos syndrome (cEDS) is a rare autosomal dominant connective tissue disorder that
is primarily characterized by skin hyperextensibility, abnormal wound healing/atrophic scars, and joint
hypermobility. A recent study demonstrated that more than 90% of patients who satisfy all of these major criteria
harbor a type V collagen (COLLV) defect.
Methods: This cohort included 40 patients with cEDS who were clinically diagnosed according to the Villefranche
nosology. The flowchart that was adopted for mutation detection consisted of sequencing the COL5A1 gene and, if
no mutation was detected, COL5A2 analysis. In the negative patients the presence of large genomic
rearrangements in COL5A1 was investigated using MLPA, and positive results were confirmed via SNP-array analysis.
Results: We report the clinical and molecular characterization of 40 patients from 28 families, consisting of 14
pediatric patients and 26 adults. A family history of cEDS was present in 9 patients. The majority of the patients
fulfilled all the major diagnostic criteria for cEDS; atrophic scars were absent in 2 females, skin hyperextensibility was
not detected in a male and joint hypermobility was negative in 8 patients (20% of the entire cohort). Wide inter-
and intra-familial phenotypic heterogeneity was observed. We identified causal mutations with a detection rate of
approximately 93%. In 25/28 probands, COL5A1 or COL5A2 mutations were detected. Twenty-one mutations were in
the COL5A1 gene, 18 of which were novel (2 recurrent). Of these, 16 mutations led to nonsense-mediated mRNA
decay (NMD) and to COLLV haploinsufficiency and 5 mutations were structural. Two novel COL5A2 splice mutations
were detected in patients with the most severe phenotypes. The known p. (Arg312Cys) mutation in the COL1A1
gene was identified in one patient with vascular-like cEDS.
Conclusions: Our findings highlight that the three major criteria for cEDS are useful and sufficient for cEDS clinical
diagnosis in the large majority of the patients. The borderline patients for whom these criteria fail can be diagnosed
when minor signs of connective tissue diseases and family history are present and when genetic testing reveals a
defect in COLLV. Our data also confirm that COL5A1 and COL5A2 are the major, if not the only, genes involved in
cEDS.
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Classic Ehlers–Danlos syndrome (cEDS) (MIM #130000) is
a rare autosomal dominant disorder with a prevalence of 1/
20,000 and is characterized by skin hyperextensibility, wid-
ened atrophic scars, and generalized joint hypermobility,
which are the major criteria of the Villefranche nosology
[1,2]. Joint hypermobility is assessed according to the
Beighton scale [2]. Other prominent features of cEDS in-
clude smooth, velvety skin, molluscoid pseudotumors, sub-
cutaneous spheroids, complications of joint hypermobility
(e.g., sprains, dislocations/subluxations, pes planus), muscle
hypotonia, delayed gross motor development, easy bruising,
manifestations of tissue extensibility and fragility (e.g., hiatal
hernia, mitral valve prolapse, anal prolapse in childhood,
cervical insufficiency, rectal and uterine prolapse), surgical
complications (postoperative hernias), and positive family
history. The clinical manifestations range in severity,
and families with mild to severe expression have been
described [1-6].
Muscle hypotonia and delayed gross motor develop-
ment can be early presentations of the disorder, as can
uni- or bi-lateral hip dislocations. Certain adults also
suffer from chronic musculoskeletal pain. Pregnancy and
delivery may present complications, especially in the
more severe forms. Premature rupture of membranes
can occur, and there is an increased risk for extension of
the episiotomy, tearing of the perineal skin, and pelvic
prolapses. Aortic ring dilatation, large-size arterial aneu-
rysms and dissections, intracranial aneurysms, and
arterio-venous fistulas have rarely been observed [3-9].
There is a significant clinical overlap of cEDS with
other EDS variants, especially hEDS. In hEDS, generalized
joint hypermobility with complications, such as repetitive
dislocations and chronic articular pain, are the primary
clinical manifestations. In this condition, the skin abnor-
malities are generally subtler than in cEDS given that the
skin is generally poorly extensible, and atrophic scars
present post-surgically [1,10, our unpublished results].
The molecular basis of cEDS is essentially a deficiency
of type V collagen (COLLV), which is a quantitatively
minor fibrillar collagen that is widely distributed in a var-
iety of connective tissues [11]. The major variant of
COLLV is a heterotrimer that is composed of two pro-α1
(V) chains and a single pro-α2(V) chain, wich are encoded
by the COL5A1 and COL5A2 genes, respectively. COLLV
plays a central role in collagen fibrillogenesis and co-
assembles with type I collagen (COLLI) to form hetero-
typic fibrils. The entire triple helical domain of COLLV is
buried within the heterotypic fibril, and only the N-
terminal NH2-propeptide is exposed at the surface [12,13].
The NH2-propeptide includes the α1(V)-N-propeptide,
which is composed of four domains: the N-terminal
thrombospondin-1-like (TSPN-1), the variable (VAR) do-
main, the small interrupted collagenous (COL2) and non-collagenous (NC2) domains, and the α2(V)-N-propeptide,
which consists of one cysteine-rich domain (CR). Following
proteolytic processing by Bone Morphogenetic Protein-1
and furin, the mature α1(V)-chain retains the VAR, COL2,
and NC2 domains; the mature α2(V)-chain retains the CR
domain [14]. The NH2-propeptide has a key regulatory
function in fibril assembly. This propeptide regulates the
diameter of the heterotypic I/V collagen fibrils and is es-
sential for interactions of COLLV with the other compo-
nents that are involved in the maintenance of ECM
architecture [12-16]. Ultrastructural examination of skin
from patients with cEDS reveals irregular and loosely
packed collagen fibrils and the presence of typical “cauli-
flower” fibrils, which represent the histological hallmark of
the disturbed fibrillogenesis of the heterotypic collagen
fibrils [17].
Recently, a comprehensive molecular study demon-
strated that over 90% of the patients strictly satisfy the
three major criteria for cEDS and harbor a COLLV defect
[18]. The most recent update of the LOVD Ehlers–Danlos
Syndrome Variant Database lists 117 different mutations
that affect COLLV. Specifically, 100 distinct COL5A1
(approximately 85%) and 17 COL5A2 mutations are de-
scribed (http://www.le.ac.uk/genetics/collagen/, November
2012, [19]). Whereas COL5A1 mutations are scattered
throughout the gene, all of the COL5A2 mutations are lo-
cated within the triple helix domain, except for one muta-
tion in the C-propeptide [4]. Defects in COL5A1 are most
commonly null mutations, consisting of either nonsense,
frameshift or splice site mutations that introduce a prema-
ture termination codon (PTC). This latter type of muta-
tion generates an unstable transcript that is rapidly
degraded by NMD and results in an overall reduction in
COLLV levels (i.e., haploinsufficiency) [4,8,18,20-27]. Only
a small number of missense or in-frame exon-skipping
splice mutations are described for COL5A1 [4,9,18,28,29];
in contrast, nearly all of the COL5A2 mutations reported
to date represent missense or in-frame exon-skipping
splice mutations, which result in the production of mutant
α2(V)-chains that are expected to incorporate into
COLLV molecules [4,18,25,26,30-32]. Although the major-
ity of COL5A1mutations are null mutations, certain struc-
tural COL5A1 mutations can reduce the amount of
normal COLLV that is available in the ECM. Specifically,
leucine substitutions in the signal peptide domain of the
pre-pro-α1(V)-chain were demonstrated to impair the se-
cretion of mutant COLLV [4,33]. Moreover, mutations
that result in the deletion of a highly conserved cysteine in
the C-terminal propeptide prevent the incorporation of
the mutant pro-α1(V) chains into the molecule [18,21,26].
A notable type of COL5A1 mutations is represented by 3
splicing errors within the highly conserved α1(V)-N-
propeptide. These errors result in several in-frame splice
transcripts that are expressed and secreted into the
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action of these N-propeptide mutations is less well under-
stood, as are the triple helix substitutions that result from
either COL5A1 or COL5A2 mutations. These mutations
are predicted to result in the production of mutant α1
(V) or α2(V)-collagen chains that interfere with the for-
mation of COLLV heterotrimers. In turn, secreted mu-
tant heterotrimers are predicted to exert a dominant
negative effect, perturbing the heterotypic fibril forma-
tion and the interactions of COLLV with other ECM
constituents [4,16,18,32-35].
To date, no clear genotype-phenotype correlations for
COLLV defects in patients with cEDS have emerged. Al-
though the number of patients with a COL5A2 mutation
is limited compared to the number of patients who har-
bor a COL5A1 defect, recently published results indicate
that COL5A2 mutation carriers fall within the more severe
end of the phenotypic spectrum of cEDS [18]. Certain pa-
tients with a mild presentation are also reported but a de-
tailed clinical presentation is lacking [4,18,31,32].
Mutations in certain other connective tissue genes,
such as COL1A1 and TNXB, have been described to cause
phenotypes that strongly overlap with cEDS. However,
these mutations appear to be very rare, especially TNXB
mutations. Moreover, the associated phenotypes exhibit
certain differences from those of COLLV-associated cEDS
[11,36,37]. Specifically, missense mutations in COL1A1
that result in the substitution of an arginine residue in the
Xaa position of the Gly-Xaa-Yaa repeat with a cysteine,
causing a dominant negative effect, cause a cEDS pheno-
type with a propensity for arterial rupture in young adult-
hood (i.e., vascular-like cEDS) [3,6,11,36,38].
Here, we report the clinical and molecular findings for
40 patients with cEDS from 28 families. The present re-
sults support the recently published data by Symoens
et al. [18], confirming that COL5A1 and COL5A2 muta-
tions are responsible for more than 90% of cEDS cases.
In this cohort, we demonstrate that the three major
diagnostic criteria are effective in reaching a clinical
diagnosis in the majority of such patients.
Materials and methods
Patients
All of the subjects provided written, informed consent
and authorized the processing of their personal data
according to Italian bioethics laws and the Declaration
of Helsinki Principles were respected. The cohort in-
cluded 38 patients of Italian origin and two children,
one from Morocco and the other from Moldavia, who
were referred to the Genetics Service of the University
of Brescia and to the Center for Heritable Connective
tissue disorders and Ehlers–Danlos syndrome at the
Dermatology Department of the Spedali Civili of Brescia.
All of the patients were recruited and examined bothclinically and at the molecular level within the past 3
years. Detailed clinical records and family histories were
obtained for all of the patients according to the Ville-
franche nosology. The presence of the three major
criteria for cEDS, i.e., skin hyperextensibility, widened
atrophic scars, and generalized joint hypermobility, was
evaluated. The presence of the minor cEDS criteria was
also ascertained, including the following: a history of de-
layed gross motor development; dysmorphic signs, e.g.,
blue sclerae, micro-retrognathia, epicanthal folds, and high
palate, etc.; dermatological signs, i.e., smooth and velvety
skin, easy bruising, molluscoid pseudotumors, piezogenic
papules, striae distensae; articular and skeletal signs, i.e.,
pectus excavatum, valgus knee, pes planus, hallux valgus,
kypho/scoliosis, joint dislocations/subdislocations, and
chronic articular pain; cardiovascular signs, i.e., valvular re-
gurgitation, mitral valve prolapse; and other features, e.g.,
chronic fatigue syndrome and gastrointestinal involvement
(Table 1) [2,3,6,18].
Isolation of the DNA/RNA and mutational analysis
Genomic DNA (gDNA) was purified from blood samples
of affected and unaffected family members using a Wiz-
ard Genomic DNA purification Kit (Promega, Madison,
WI, USA) using standard procedures. For one patient
(AN_002533), a fibroblast culture was established from a
skin biopsy, as previously described [39]. The total RNA
was isolated from patients’ skin fibroblasts using TRIzol
reagent (Life Technologies Carlsbad, CA, USA) and was
retrotranscribed in the presence of random hexanucleotide
primers and MMLV-RTase (Invitrogen, Life Technologies)
using standard procedures.
The primers were designed for all of the coding exons,
including the intron-exon boundaries, and for the 5’ and
3’ UTRs near the coding sequence (a minimum of 200
bp). The primers were designed using a combination of
the Primer3 (http://frodo.wi.mit.edu/) and PrimerZ
(http://genepipe.ngc.sinica.edu.tw/primerz/) tools. The pri-
mer sequences were analyzed for the absence of known
variants, such as single nucleotide polymorphisms (SNPs),
using dbSNP version 135 (www.ncbi.nlm.nih.gov/projects/
SNP/). All of the exons and intron-flanking regions of the
COL5A1, COL5A2 and COL1A1 genes were amplified with
standardized PCR using optimized genomic primer sets
and the GoTaq Ready Mix 2X (Promega) to generate 55,
49 and 30 separate PCR fragments, respectively (primer se-
quences and amplification profiles are available upon re-
quest). Following the enzymatic cleanup of the PCR
products by ExoSap-ITW (Affymetrix UK Ltd, Wycombe
La High Wycombe, UK), all of the fragments were se-
quenced in both orientations using the BigDyeW Termin-
ator Cycle Sequencing kit protocol (Life Technologies),
and PerformaW DTR Ultra 96-Well Plates (EdgeBio,
Gaithersburg, MD, USA) were used for PCR cleanup. This
Table 1 Clinical findings of the 40 patients with cEDS
Patient IDs Sex/Age (y) Family
history
Hyperextensible
smooth skin
Scars Joint
hypermobility
Beighton score
Other features
AN_002501 F/15 - + + A + (9/9) Easy bruising, Striae distensae,
Piezogenic papules, Pes planus,
Dislocations, Chronic articular pain
AN_002502 F/29 - + + A + (7/9) Hypotonia at birth, Delayed motor
development, Blue scleraea,
Hypertelorism, Epicanthus, Micrognathia,
Hypermetropia, Astigmatism, Reduced
anterior chamber depth, Easy bruising,
Piezogenic papules, Palmar creases,
Hands and feet deformity, Scoliosis,
Spondylolisthesis, Hallux valgus, Pes
planus, Renal ptosis, Gastroesophageal
reflux
AN_002503
father of
M/40 + + + A + (9/9) Thin lips, Easy bruising, Molluscoid
pseudotumor (elbow), Piezogenic
papules, Pes planus, Varicose veins
AN_002504
sister of
F/13 + + + A (one) + (9/9) Epicanthus, Micrognathia, Easy bruising,
Piezogenic papules, Pes planus
AN_002505 F/6 + + Doughy + A, H + (9/9) Epicanthus, Micrognathia, Easy bruising,
Piezogenic papules, Pes planus
AN_002506 M/24 - + Doughy + A + (5/9) Bleeding gums, Dysphonia, Myopia, Easy
bruising, Piezogenic papules, Hallux
valgus, Pes planus, Osteoporosis,
Dislocations (recurrent), Severe chronic
articular pain (daily therapy with FANS),
Aortic regurgitation, Mitral valve
prolapse, Inguinal hernia, Chronic
fatigue syndrome
AN_002507
daughter of
F/10 + + Doughy + A + (9/9) High palate, Mild prognathism, Easy
bruising, Dental malocclusion treated
with byte
AN_002508 F/40 + + Doughy - + (5/9) Blue sclerae, Striae distensae, Easy
bruising, Mild scoliosis, Transitional
lumbosacral vertebra, Subdislocations
(sporadic), Low back pain, Chronic
sinusitis, Atopy, Hashimoto’s thyroiditis,
Melanoma treated with surgery
AN_002509 M/5 - + Doughy + A + (8/9) Blue sclerae, Mild hypertelorism,
Micrognathia, Low-set ears, Easy
bruising, Piezogenic papules, Valgus
knee, Mobile testis, Atopic dermatitis
AN_002510 M/4 - + Doughy + A + (9/9) Delayed motor development, Blue
sclerae, Easy bruising, Piezogenic
papules, Pes planus, Gastroesophageal
reflux, Umbilical hernia
AN_002511 F/15 - + Doughy + A (one) + (8/9) Blue sclerae, Easy bruising,
Arachnodactyly, Mild scoliosis, Valgus
knees, Pes valgus and cavus,
Subdislocations, Syonvitis (hip), Chronic
articular pain, Posterior cerebral artery
hypoplasia, Anal fissures
AN_002512
mother of
F/41 + + - - (2/9) Blue sclerae, Epicanthus, High palate,
Myopia, Easy bruising, Striae distensae,
Piezogenic papules, Hallux valgus, Pes
planus, Chronic fatigue syndrome
AN_002513 M/10 + + Doughy + A + (8/9) Blue sclerae, Epicanthus, Myopia, Mild
strabismus, Micro/retrognathia, High
palate, Easy bruising, Piezogenic
papules, Pectus excavatum, Winged
scapulae, Kyphosis, Pes planus, Mitral
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valve prolapse, Tricuspid and pulmonary
regurgitation, Atrio-ventricular block (1st
and 2nd degree), Umbilical hernia treated
with surgery, Chronic fatigue syndrome
AN_002514 F/34 - + + A + (5/9) Easy bruising, Plantar creases, Scoliosis,
Sacroiliitis, Subdislocations, Chronic
articular pain, Right pulmonary artery
hypoplasia, Spontaneous abortion (12 w)
AN_002515 F/7 - + Doughy + A + (7/9) Epicanthus, Hypertelorism, Micrognathia,
Easy bruising, Hallux valgus, Mobile
patella, Mild scoliosis, Pes planus
AN_002516 F/67 - + Loose + A + (8/9) Easy bruising, Deep venous thrombosis,
Hypertension, Menometrorrhagia and
hysterectomy, Multiple myeloma and
death for renal failure (67 y)
AN_002517 F/33 - + Doughy, Thin + A - (2/9) Blue sclerae, Astigmatism, Palmar
creases, Easy bruising, Piezogenic
papules, Mild scoliosis, Pes planus,
Cervical disc hernias with articular
blocks, Subdislocations (sporadic),
Chronic articular pain, Osteopenia,
Muscle hypotonia, Acrocyanosis, Mild
mitral, tricuspid and pulmonary
regurgitation, Menometrorrhagia,
Gastroesophageal reflux, Periodontitis
AN_002518
mother of
F/37 + + Doughy + A + (9/9) High palate, Low set ears, Micrognathia,
Easy bruising, Piezogenic papules, Mild
scoliosis, Subdislocations, Discal hernias,
Chronic articular pain, Constipation
AN_002519 M/5 + + Doughy + A + (9/9) High palate, Epicanthus, Micrognathia,
Easy bruising, Piezogenic papules,
Winged scapulae, Pes planus
AN_002520
sister of
F/9 + + Doughy + A + (5/9) Hypotonia at birth, Blue sclerae,
Micrognathia, Myopia, Easy bruising,
Dislocations, Chronic articular pain
(knees)
AN_002521
son of
M/7 + + Doughy + A + (5/9) Hypotonia at birth, Blue sclerae,
Micrognathia, Easy bruising, Dislocations
AN_002522
son of
M/35 + + + A - (3/9) Blue sclerae, Micrognathia, Easy bruising,
Dislocations
AN_002523 F/60 + + Loose + A - (3/9) Blue sclerae, Easy bruising,
Polyabortivity, Dislocations, Chronic pain
AN_002524 F/21 - + Doughy + A, H + (7/9) Blue sclerae, Epicanthus, Micrognathia,
Anteverted nostrils, Easy bruising,
Chronic headache
AN_002525 M/7 - + Doughy + A + (7/9) Blue sclerae, High palate, Mild
epicanthus, Easy bruising, Piezogenic
papules, Valgus knee, Hallux valgus,
Mobile patella, Pes planus, Dislocations
(sporadic)
AN_002526 M/46 - + Doughy + A - (4/9) Blue sclerae, High palate, Micro-
retrognathia, Easy bruising,
Onychodystrophy, Piezogenic papules,
Mild scoliosis, Spondylolisthesis,
Severe bilateral hallux valgus,
Pes cavus, Dislocations (recurrent),
Chronic and generalized pain,
Arthrosis, Tendinopathy, Carpal tunnel
syndrome, Chronic fatigue syndrome,
Hypertension, Diabetes mellitus type II
with retinopathy, Recurrent caries,
Cataract
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AN_002527 M/48 - + Doughy + A + (9/9) Easy bruising, Palmar creases, Mild
scoliosis, Arthrosis, Gastroesophageal
reflux, Periodontitis
AN_002528
twin of
F/36 - + Doughy + A + (7/9) Hypotelorism, Myopia, Easy bruising,
Piezogenic papules, Pectus excavatum,
Mild scoliosis, Pes planus,
Subdislocations, Chronic articular pain,
Osteopenia, Aortic, tricuspid and
pulmonary regurgitation, Mitral valve
prolapse, Polyabortivity, Amenorrhea
(high prolactin), Hereditary
thrombophilia
AN_002529 F/36 - + Doughy + A + (8/9) Hypotelorism, Myopia, Easy bruising,
Piezogenic papules, Pectus excavatum,
Mild scoliosis, Pes planus,
Subdislocations, Chronic articular pain,
Osteopenia, Aortic, tricuspid and
pulmonary regurgitation, Mitral valve
prolapse, Polyabortivity, Hereditary
thrombophilia
AN_002530
mother of
F/43 + + Doughy + A + (9/9) Easy bruising, Talipes equinovarus
treated with surgery, Mild scoliosis,
Hypoplasia of upper femur, Coxa valga,
Hip prosthesis, Arthrosis,
Subdislocations, Chronic articular pain
(daily therapy), Tricuspid regurgitation,
Gastroesophageal reflux, Chronic
gastritis, Polyabortivity, Cervical
dysplasia (CIN2) treated with surgery,
Atopy
AN_002531 M/9 + + Doughy + A, H + (7/9) Epicanthus, Easy bruising, Piezogenic
papules, Talipes equinovarus treated with
surgery, Mild scoliosis, Pes planus and
valgus, Tachycardia, Gastroesophageal
reflux
AN_002532 F/7 - + + A, H - (4/9) Epicanthus, Blue sclerae, High palate,
Micrognathia, Easy bruising
AN_002533 M/21 - + + A + (6/9) Epicanthus, High palate, Strabismus,
Hypermetropia, Anteverted nostrils,
Micro-retrognathia, Easy bruising,
Molluscoid pseudotumor, Mild pectus
excavatum, Scoliosis, Ulnar deviation,
Asymmetric legs, Hands and feet and
deformity, Hallux valgus, Pes planus,
Enthesopathies (recurrent), Dislocations
(recurrent), Chronic articular pain,
Chronic fatigue syndrome
AN_002534 F/39 - + Doughy Thin + A, H + (9/9) Anisocoria, Easy bruising, Piezogenic
papules, Short stature, Severe
congenital kyphoscoliosis treated with
surgery (arthrodesis), Bilateral valgus
knees, Severe hallux valgus, Pes planus,
Recurrent generalized dislocations,
Vertebral dislocations treated with
surgery, Hip periarthritis, Arthrosis,
Tendinopathy (recurrent),
Enthesopathies (recurrent), Osteoporosis,
Chronic articular pain (sporadic FANS
and opioids therapy), Muscle hematomas
and rupture, Mitral valve prolapse,
Deep venous thrombosis, Chronic
fatigue syndrome, Urethral and
rectal prolapse, Recurrent
hemorrhagic cystitis
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AN_002535
brother of
M/20 + + Doughy + A + (7/9) Delayed anterior fontanelle closure,
Epicanthus, High palate, Hypoplastic
uvula, Easy bruising, Bilateral molluscoid
pseudotumor (elbow), Arachnodactyly,
Scoliosis, Pectus excavatum (marked),
Toes deformities, Mobile patella, Pes
planus, Dislocations (sporadic), Mitral
valve prolapse, Chronic fatigue syndrome,
Atopy, Dysphagia, Epileptic seizures
AN_002536
daughter of
F/11 + + Doughy + A + (7/9) Blue sclerae, High palate, Micrognathia,
Easy bruising, Bilateral molluscoid
pseudotumor (elbow), Arachnodactyly,
Mild scoliosis, Pes planus, Toes
deformities
AN_002537 M/53 + - Doughy + A - (0/9) Hypotonia at birth, Blue sclerae,
Piezogenic papules, Hallux valgus, Pes
planus, Gastrocnemius muscle rupture,
Achilles tendon rupture, Enthesopathies
(left knee, recurrent), Deep venous
thrombosis, Hypertension (beta-blockers
treatment)
cEDS1 F/65 + + Loose, wrinkled + A – (2/9) Blue sclerae, Easy bruising, Piezogenic
papules, Mild scoliosis, Hallux valgus
treated with surgery, Subdislocations
(sporadic), Chronic articular pain, Carotid
stenosis in antiaggregant therapy
cEDS2 F/4 - + Doughy + A + (9/9) Epicanthus, Blue sclerae, Anteverted
nostrils, Easy bruising, Dislocations
(sporadic)
cEDSv-l1 M/53 + + Doughy + A + (6/9) Blue sclerae, High palate, Hypoplastic
uvula, Easy bruising, Piezogenic papules,
Molluscoid pseudotumor (elbow), Pectus
excavatum, Severe left hallux valgus, Pes
planus, Dislocations (sporadic), Chronic
articular pain, Chronic perimalleolar
lymphedema, Varicose veins, Mild mitral
and aortic regurgitation, Left ventricular
wall thickening, Aortic root ectasia,
Vertebral artery tortuosity, Hepatic
hemangioma, Chronic fatigue syndrome,
Gastroesophageal reflux, Hiatal and
abdominal hernias, Right inguinal hernia
treated with surgery
Abbreviations: A: atrophic scars; H: hypertrophic scars; y, years; w, weeks. Patient(s) ID AN_002501-37 correspond to the identifiers submitted in the LOVD EDS
Variant Database (http://www.le.ac.uk/ge/collagen/); cEDS1-2: patients without identified causal mutation, not registered in LOVD; cEDSv-l1: vascular-like cEDS
patient with COL1A1 causal mutation. a: In all of the patients the blue of the sclerae was faint.
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ABI3130XL Genetic Analyzer (Life Technologies). Fur-
thermore, to verify the effect of an identified splice mu-
tation, RT-PCR was performed using RNA that was
isolated from patients’ skin fibroblasts using standard
procedures. Specifically, the amplification of cDNA cov-
ering exons 36–38 of the COL5A2 gene was performed.
When a mutation was identified, the parents and un-
affected family members of the proband were examined.
All of the identified mutations were confirmed to not be
novel polymorphisms based on the analysis of 200 al-
leles from healthy Italian donors and were submitted to
the LOVD Ehlers–Danlos Syndrome Variant Database.
The nucleotide and protein accession numbers corres-
pond to the COL5A1 (NM_000093.3, NP_000084.3),COL5A2 (NM_000393.3, NP_000384.2) and COL1A1
(NM_000088.3, NP_000079.2) reference sequences. The
mutations were annotated according to HGVS nomen-
clature (www.hgvs.org/mutnomen). The nucleotide
numbering is based on cDNA sequence numbering,
with +1 corresponding to the A of the ATG translation
initiation codon 1 in the reference sequence. For pro-
tein numbering, +1 corresponds to the first translated
amino acid. The sequences were analyzed using the
Sequencher 4.9 software (www.genecodes.com) and/or the
Mutation Surveyor tool (www.SoftGenetics.com). The
sequence descriptions from all of the mutations and poly-
morphisms were verified using Mutalyzer (www.LOVD.nl/
mutalyzer). We used mutation prediction programs, such
as MutationTaster (www.mutationtaster.org), PolyPhen-2
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jcvi.org/) and Alamut software version 2.2 (www.inter-
active-biosoftware.com), to evaluate causality based on the
alteration of the protein structure. Project HOPE (www.
cmbi.ru.nl/hope/home), a server that provides insight in
the structural effects of mutations, was also used [40]. To
evaluate splice site mutations, we used four prediction pro-
grams (SpliceSite-Finder-like, MaxEntScan, NNSPLICE
and Human Splicing Finder) in Alamut Software.
MLPA and SNP-array analyses
For the multiplex ligation-dependent probe amplification
(MLPA), the commercially available SALSA MLPA kits
P331-A1/P332-A1 for the COL5A1 gene were usedFigure 1 Cutaneous and articular features in patients with cEDS. a-d)
and the knee; e-h) different scar types, small atrophic, atrophic and hypertr
the knees and pretibial area in a pediatric and an adult patient; k-n) hyperm
pediatric patient; o-p) molluscoid pseudotumors; q) piezogenic papules.(MRC-Holland, Amsterdam, The Netherlands). The
MLPA was performed in duplicate, according to the man-
ufacturer’s recommendations (www.mrc-holland.com),
using 100 ng of gDNA. The P331 and P332 probemixes
did not contain probes for exons 12, 33, 36, 49, 54, and
66. MLPA-generated fragments were separated by capil-
lary electrophoresis on an ABI3130XL Genetic Analyzer
using 500 LIZW as an internal size standard (Life Tech-
nologies). The results were analyzed using GeneMarkerW
software version 2.2.0 (SoftGenetics, State College, PA,
USA). Deletions and duplications of the targeted exons
were detected when the height ratios of the fluorescent
peaks were lower or higher, respectively, than the normal
height ratio range of 0.75-1.30.marked skin hyperextensibility on the neck, the forearm, the elbow,
ophic, hypertrophic and haemosiderotic; i, j) scars and easy bruising of
obility of the little finger, the thumb, the elbow and the knee in a
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Affymetrix Human Mapping GeneChip 6.0 array that
contains a total of 2 million probes, half of which were
polymorphic. The DNA was processed according to the
manufacturer’s instructions (Affymetrix UK Ltd). To ob-
tain intensity data, the array analysis was performed
using Affymetrix GeneChip Command Console Software
(AGCC). The AGCC probe cell intensity data were then
analyzed using Genotype Console 3.01 (GTC3.01) to
obtain genotype data. Quality thresholds were used to
reduce the number of genotype errors, and the copy
number (CN) state calls were generated from the
BRLMM-P-Plus algorithm, which was implemented in
GTC 3.0.1. This algorithm compares the intensity signal
of each marker in each sample against a reference pool
formed from a group of 270 samples derived from the
HapMap database. Next, the software generates a me-
dian intensity value for each marker, which is reported
as the log2 ratio of the CN state. The CN state informa-
tion was then used by the Affymetrix segmentation algo-
rithm to identify CNVs. To reduce the risk possibility of
false-positive CNVs, the segmentation algorithm param-
eters were set to consider CNVs as only those regions
larger than 100 kb, consisting of at least 25 contiguous
markers without a diploid state, and with an average
probe density lower than 10 kb.
Results
Clinical findings
A cohort of 40 patients with cEDS from 28 families were
clinically evaluated (Table 1). Of the patients, there were
16 males and 24 females, 14 pediatric patients, i.e., less
than 12 years of age, and 26 adults. A family history of
cEDS was present in 9 probands. Patients AN_002528
and AN_002529 were 36-year-old monozygotic twin sis-
ters. Smooth and hyperextensible skin on the neck, the
forearm, the elbow and the knee was present in all of
the patients to various degrees, with the only exception
being patient AN_002537. In 51% of the positive pa-
tients, either pediatric or adult, the skin was markedly
hyperextensible. In 18% of the patients, the skin was
poorly hyperextensible (28% pediatric, and 12% adult)
(Figure 1 a-d, Table 1). Skin fragility that led to defective
scarring was observed in 95% of the patients (scars were
absent in 2 adult females, AN_002508 and AN_002512;
2.4%) (Table 1). The scar presentations were variable
with respect to type, localization, and number. Three
different types of scars were observed: atrophic (small
and large size, in 95% of the patients), haemosiderotic
(18%, all in adults, except one), and hypertrophic (13%,
primarily pediatric) (Figure 1 e-h). The sites presenting
the highest incidence of scar formation were those that
are most susceptible to major traumatism, i.e., the fore-
head (56% children and adults, with no difference betweenthese groups), the knees (82%, in both children and adults)
and the pretibial area (93% children, 76% adults) (Figure 1
i, j). A total of 50% of the pediatric patients and 35% of the
adults presented with scars in all of these areas. The adults
exhibited the most severe presentations. In 28% of the
pediatric patients, defective scars were also observed in
other sites (e.g., the chin, the elbow, and the wrist). The el-
bows, forearm, and thighs were affected in only 7% of the
adults. Nearly all of the patients exhibited multiple aber-
rant scars. Only one small atrophic scar was present in
two adult females (AN_002504 and AN_002511).
With respect to joint hypermobility, 32/40 patients
fulfilled the Beighton score (80%) (Figure 1 k-n). In
approximately 60% of the adult patients, this feature was
associated with recurrent/sporadic dislocation(s)/sub-
dislocation(s) with or without chronic or sporadic articu-
lar pain (Table 1). Only one adult male reported sporadic
joint dislocations without pain (AN_002535). Four children
(29% of the pediatric patients: AN_002520, AN_002521,
AN_002525, and cEDS2) had events of dislocation/
subdislocation, and one of these patients (AN_002520) ex-
perienced chronic pain of the knees (Table 1). None of the
patients required daily therapy, except for one adult male
(AN_002506), who was treated with FANS. The other pa-
tients required sporadic pain therapy with FANS. For one
patient (AN_002534), who had the most severe phenotype,
opioid therapy was administered following several wide-
spread dislocations and two events of muscle rupture
(Table 1).
The additional clinical manifestations included the fol-
lowing: dysmorphic signs (21/40 blue sclerae, 16/40
micro-retrognathia, epicanthal folds in 8/14 pediatric pa-
tients and in 6/26 adults, and 12/40 high palate); cutane-
ous signs (39/40 easy bruising, 26/40 doughy skin, 22/40
piezogenic papules, 5/40 molluscoid pseudotumors, 3/40
loose skin, and 3/40 striae distensae) (Figure 1 o-q); ar-
ticular and skeletal signs (22/40 pes planus, 18/40
(kypho)scoliosis, 11/40 hallux valgus, 6/40 mild pectus
excavatum, and 4/40 valgus knee); cardiovascular signs
(7/40 valvular regurgitation, 6/40 mitral valve prolapse);
and other signs (8/40 chronic fatigue syndrome, 6/40
gastroesophageal reflux; 5/40 hypotonia at birth; 4/40
hernias; and 2/40 delayed motor development) (Table 1).
Spheroids were not evaluated.
Further findings were present in three subjects. Patient
AN_002502 exhibited the following signs: i) ocular in-
volvement, i,e., reduced anterior chamber depth, hyper-
metropia and astigmatism; ii) facies sui generis, with the
presence of severe epicanthus, blue sclerae, hypertelorism
and micrognathia; iii) skeletal abnormalities (arthrosis-like
deformities of the hands and feet, scoliosis, hallux valgus)
and spondylolisthesis; iv) hypotonia at birth with delayed
motor development; and v) renal ptosis (Figure 2A, a-g;
Table 1).
Figure 2 Clinical findings in two patients with cEDS. A) Patient AN_002502, with ocular involvement and a, b) dysmorphic features, including
epicanthus, blue sclerae, hypertelorism, micrognathia; c-d) skin hyperextensibility; e) easy bruising and atrophic and hypertrophic scars on the
knees and pretibial area; f, g) hand and foot deformities, hallux valgus. B) Patient AN_002534 with a severe phenotype; a, b) atrophic and
hypertrophic scars on the forehead and the cheeks at the age of 32 years; c) marked skin hyperextensibility on the forearm; d) redundant and
sagging skin on the ankles and hallux valgus; e) scars (all types) on the knees and inferior limbs; f) hypermobility of the forefinger; g) outcomes of
severe congenital kyphoscoliosis treated with surgery, bilateral valgus knee, scars on the elbows, the forearms, redundant and sagging skin on
the ankles, and flat feet.
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overlapping with Marfan syndrome, i.e., arachnodactyly,
marked pectus excavatum, and other uncommon features of
cEDS, i.e., delayed anterior fontanelle closure, epileptic sei-
zures and hypoplastic uvula. The sister of this patient(AN_002536) also presented with arachnodactyly. The father
(AN_002537) did not exhibit skeletal involvement; he expe-
rienced spontaneous gastrocnemius muscle and Achilles’
tendon rupture and exhibited recurrent enthesopathies (left
knee), deep venous thrombosis, and hypertension (Table 1).
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vascular involvement than is generally observed in cEDS,
i.e., aortic root ectasia, vertebral artery tortuosity, left
ventricular wall thickening, mild mitral and aortic regur-
gitation, and hepatic hemangioma (Table 1). This patient
reported two first paternal cousins with abnormal scar-
ring who were both dead at 32 years from cerebral an-
eurism rupture; their mother exhibited abnormal
scarring and died at 70 years from an unspecified vascu-
lar disease.
Patients AN_002533 and AN_002534 were 21 and 39
years old, respectively, and presented an extremely severe
phenotype, including failure to thrive, marked involve-
ment of the cutaneous and musculoskeletal systems,
chronic pain, and chronic fatigue syndrome (Table 1). Spe-
cifically, the 39-year-old patient (AN_002534) exhibited
severe congenital kyphoscoliosis and vertebral dislocations
that were both treated with surgery, hip periarthritis,
osteoporosis, arthrosis, short stature (1.41 m, below the
3rd percentile), rectal and urethral prolapse, deep venous
thrombosis, two events of muscle rupture, and hemato-
mas (Figure 2B, a-g).
During childhood, cutaneous involvement was the
most prominent sign in the majority of the patients; the
phenotype worsened in the teenage years and adulthood
with various degrees of musculoskeletal and systemic
features. Neither severe aneurysmatic dilatation nor ar-
terial rupture were present.
Wide intrafamilial phenotypic heterogeneity was ob-
served and was most remarkable in AN_002507 and
AN_002513 patients’ mothers, who were apparently un-
affected based on the absence of scars and for whom the
only presence of musculoskeletal signs did not suggestFigure 3 Diagnostic flowchart adopted in this study. The
diagnostic strategy was based on the clinical evaluation of the
patients followed by COL5A1 sequencing, which detected the causal
mutation in the large majority of the cases. COL5A2 was investigated
when COL5A1 analysis was negative; MLPA analysis was performed
when the two previous analyses were not able to detect the
causal mutation.the presence of the disorder until cEDS was diagnosed
for their children (Table 1). Patient AN_002537 differed
primarily from his two affected children in that he did not
exhibit skin hyperextensibility and joint hypermobility
(Table 1).
The phenotypes of AN_002528 and AN_002529, who
were twin sisters, were nearly completely overlapping
and showed signs of a full presentation of the disorder
(Table 1).
Molecular characterization and genotype-phenotype
correlations
The flowchart that was adopted for mutation detection
in the examined patients with cEDS began with direct
sequencing of the COL5A1 gene. If no mutation was
detected, COL5A2 was analyzed (Figure 3). In patients
without defects, the presence of large genomic
rearrangements in the COL5A1 gene was investigated by
MLPA, which is not commercially available for COL5A2
(Figure 3). In patients without a detected mutation but
with a clear phenotype, the clinical diagnosis of cEDS was
maintained. Other diagnoses were considered for patients
with additional signs. For example, one patient (cEDSv-l1)
had a family history of cardiovascular involvement
(Table 1), and we suspected vascular-like cEDS. This pa-
tient’s COL1A1 gene was sequenced and was found to con-
tain the previously described c.934C>T mutation. This
mutation results in an arginine-to-cysteine substitution p.
(Arg312Cys) in the α1(I)-collagen chain at the Xaa-
position of the repeating structure of the triple helical
domain.
Using this flowchart, we were able to identify the
causal mutations in our cEDS patient cohort with a de-
tection rate of approximately 93% (26/28 characterized
probands). Of the identified COL5A mutations, 91% in-
volved the COL5A1 gene. Of these, 18 were novel muta-
tions, 2 of which were detected twice in the present
study (c.2988del and c.3769C>T), and 3 were previously
reported (c.2988dup, c.3413G>A and c.3769C>T) [18;
LOVD]. Two novel splice mutations were detected in
the COL5A2 gene (Table 2). Parental testing indicated
that 14 of the 23 COL5A mutations arose de novo; for 2
mutations, de novo testing was not possible as the par-
ents were unavailable, but family history was reported to
be negative. Eight mutations were detected in families
with multiple affected members (Table 2). In two pa-
tients (cEDS1 and cEDS2), no causal mutations in the
COL5A1, COL5A2 genes were detected, although these
patients did not differ clinically from the mutation-
positive patients (Table 1).
Among the 21 COL5A1 mutations that were identi-
fied in the present study, approximately 76% were null
allele mutations that were predicted to cause COLLV
haploinsufficiency given that they should activate the
Table 2 COL5A1 and COL5A2 mutations in patients with cEDS
Patient(s) IDs Gene Exon, intron/localization a Change at the nucleotide level b Nonsense/Missense b Frameshift Splice site
Mutations leading to type V collagen haploinsufficiency
AN_002501 A1 ex1/N-propeptide c.87G>A° p.(Trp29*)
AN_002503-05# A1 int7/N-propeptide c.1165-2A>G p.(Pro389Leufs*168) c Activation of cryptic splice acceptor
site 4 bp downstream of WT acceptor
AN_002506 A1 ex13/N-propeptide c.1651C>T° p.(Gln551*)
AN_002509 A1 int31/helix c.2647-12A>G° p.(Gly883Leufs*195) c Creation of new splice acceptor site
11 bp upstream of WT acceptor
AN_002510 A1 ex34/helix c.2757_2774del18insA° p.(Glu920Hisfs*14)
AN_002511 A1 ex36/helix c.2891dup° p.(Gly967Trpfs*47)
AN_002514-15* A1 ex38/helix c.2988del° p.(Gly997Alafs*77)
AN_002516 A1 ex38/helix c.2988dup^ e p.(Gly997Argfs*17)
AN_002517 A1 ex42/helix c.3328C>T° p.(Gln1110*)
AN_002520-23# A1 ex45/helix c.3568C>T p.(Gln1190*)
AN_002524-25* A1 ex48/helix c.3769C>T° e p.(Arg1257*)
AN_002527 A1 ex62/C-propeptide c.4714del° p.(Val1572Serfs*47)
AN_002528-29# A1 ex62/C-propeptide c.4919_4928del10^ p.(Lys1640Serfs*86)
AN_002530-31# A1 ex63/C-propeptide c.4962C>G p.(Tyr1654*)
AN_002532 A1 ex66/C-propeptide c.5458_5459del° p.(Phe1820Argfs*2)
Large genomic rearrangement identified by MLPA and SNP-array
AN_002535-37# A1 chr9.hg19:g.(137,440,166_137,442,686)_(137,633,699_137,638,368)dup
Mutations affecting the structural integrity of type V collagen
AN_002502 A1 ex4/N-propeptide c.532A>C° p.(Thr178Pro)
AN_002507-08# A1 ex29/helix c.2436A>T p.(Glu812Asp) c alteration of an ESE sequence,
splice error?
AN_002512-13# A1 int37/helix c.2952+2_2952+3del p.(Gly967_Thr984del) c in-frame exon 37 skipping
AN_002518-19# A1 ex43/helix c.3413G>Ae p.(Gly1138Glu)
AN_002526 A1 ex54/helix c.4178G>A° p.(Gly1393Asp)
AN_002533 A2 ex29/helix c.1977G>A° p.(Gly642_Pro659del) c in-frame exon 29 skipping
AN_002534 A2 int37/helix c.2499+2T>C° p.(Gly816_Pro833del) d in-frame exon 37 skipping
The patient(s) IDs correspond to the identifiers found in the LOVD EDS Variant Database (http://www.le.ac.uk/ge/collagen/); a DNA mutation numbering is based on the cDNA sequence. For cDNA numbering, +1
corresponds to the A of the ATG translation initiation codon in the reference sequence. The reference sequences are based on the GenBank Accession no.: COL5A1 NM_000093.3, COL5A2 NM_000393.3. b For protein
numbering, +1 corresponds to the first translated amino acid. The reference sequences are based on GenBank Accession no.: COL5A1 NP_000084.3, COL5A2 NP_000384.2. c The effect on splicing was analyzed using
four prediction programs (SpliceSite-Finder-like, MaxEntScan, NNSPLICE and Human Splicing Finder) in Alamut software, version 2.2 (Additional file 1: Figures S1–S6). d The effect on mRNA splicing was verified by RT-
PCR of total RNA that was purified from the patient’s skin fibroblasts (Additional file 1: Figure S6B). ° de novo mutation verified by parental testing. ^ Parents not available for de novo testing. # Members of the same
family. * Members of different families. e Mutation previously reported [18, LOVD].
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Figure 4 Large genomic duplication in the COL5A1 gene. A) MLPA analysis showed the duplication of exons 1–11 of the COL5A1 gene that
was identified using the SALSA MLPA kits P331-A1 (upper panel) and P332-A1 (lower panel). The MLPA results were analyzed using GeneMarkerW
software. B) Affymetrix Human Mapping GeneChip 6.0 array analysis, which was performed to define the duplication size, revealed an
approximately 191 kb duplication, including the COL5A1 proximal promoter region: chr9.hg19:g.(137,440,166_137,442,686)_
(137,633,699_137,638,368)dup. The last normal probe (CN_1326371), the first duplicated probe (CN_1326372) at the 5’ end, the last duplicated
probe (SNP_A-1952605), and the first normal probe (CN_383563) at the 3’ end define the duplicated area.
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mutations and 7 were small genomic deletions/duplica-
tions that caused frameshift and the formation of a PTC.
Among these mutations, two affected the c.2988 position
and were present in three unrelated patients. Patients
AN_002514 and AN_002515 (both c.2988del), as well as
AN_002516 (c.2988dup), presented a complete phenotype
that was compatible with their age (Table 1). Patients
AN_002524 and AN_002525, who carried the c.3769C>T
transition [p.(Arg1257*)], presented a complete and mild
phenotype, respectively, according to their age (Table 1).
Two mRNA splicing errors that were predicted to
cause haploinsufficiency were also detected (Table 2).
We identified a c.1165-2A>G splice acceptor mutation
in intron 7 in the AN_002503-05’s family. This mutation
is predicted in silico to cause the activation of a cryptic
splice acceptor site 4 bp downstream of the canonical
site inside of exon 8, therefore generating a PTC [p.
(Pro389Leufs*168)] (Additional file 1: Figure S1). How-
ever, a more complex splicing outcome cannot be ex-
cluded; for example, in-frame exon skipping of one or
more exons, as observed for the previously reportedc.655-2A>G, c.925-2A>G, and c.925-1G>C mutations
[18,34,35], is possible. In this case this mutation should
be considered to be structural. In patient AN_002509,
the de novo c.2647-12A>G mutation in intron 31 was
predicted in silico to create a new splice acceptor site 11
bp upstream of the consensus acceptor site, with the re-
tention of the last 11 bases of intron 31, a frameshift and
PTC formation [p.(Gly883Leufs*195)] (Additional file 1:
Figure S2).
In patient AN_002535, for whom COL5A1 and COL5A2
mutations were not observed based on genomic sequen-
cing, a large genomic duplication encompassing exons 1–
11 was identified by MLPA (Figure 4A). The presence of
the duplication was confirmed by SNP-array analysis, and
its size and boundaries were defined, revealing an approxi-
mately 191 kb duplication [chr9.hg19:g.(137,440,166_137,
442,686)_(137,633,699_137,638,368)dup] that included the
COL5A1 proximal promoter region (Figure 4B, Table 2).
The duplication was inherited from the proband’s
affected father (AN_002537) and was also identified
in the patient’s affected sister (AN_002536 in Table 1).
Although the precise break point and orientation of the
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an aberrant out-of-frame mRNA splicing and consequent
haploinsufficiency.
The patients who harbored mutations that led to
haploinsufficiency generally presented complete pheno-
types, even with a given degree of age-dependent and in-
ter/intrafamilial variability. An exception to this was
patient AN_002537, who did not meet two of the major
criteria of the disorder (Table 1). Only a single scar each
was observed for patients AN_002504 and AN_002511,
who were both young adults. In patient AN_002511, that
only one scar was present this was likely due to constant
skin care and the avoidance of traumatisms since child-
hood. Patient AN_002535, who carried the large gen-
omic duplication in COL5A1, exhibited skeletal signs of
Marfan syndrome and other unusual signs. His 11-year
-old sister (AN_002536) only presented arachnodactyly,
whereas their father (AN_002537) presented with none
of these signs (Table 1).
Only approximately 24% (5/21) of the COL5A1 muta-
tions, i.e., four missense and one splice error, were
identified to affect the structural integrity of the α1(V)-
chain (Table 2). We identified a missense mutation in
the TSPN-1 domain of the α1(V)-N-propeptide in pa-
tient AN_002502. This de novo c.532A>C mutation in
exon 4 replaced the highly conserved threonine in pos-
ition 178 with a proline [p.(Thr178Pro)]. The wild type
residue is predicted to form hydrogen bonds with the
threonine at position 188 and with the asparagine at
position 176. The difference in hydrophobicity should
affect this hydrogen bond formation, the 3D-structure,
and the function of the TSPN-1 domain. This mutation
leads to a multisystem severe phenotype that includes
ocular involvement (Table 1, Figure 2A).
We detected the c.2436A>T mutation in exon 29 in
the AN_002507-08 family. This mutation replaces the
glutamic acid at position 812 with an aspartic acid [p.
(Glu812Asp)]. This highly conserved residue is located
at the X position of the G-Xaa-Yaa motif in the triple
helix domain; therefore, the mutation is predicted to
interfere with the triple helix structural integrity. This
variant is categorized by Polyphen2 as probably dam-
aging and by SIFT as deleterious. Several bioinformatics
tools suggest that this mutation alters exonic splicing en-
hancer (ESE) sequences, i.e., the SF2/ASF binding site
AAGACGG shows a decreased consensus score (3.1 vs.
1.98 by ESE-finder), and the GTGAAG and the GAAGAC
consensus sites are abolished (Rescue_ESE). Therefore, an
aberrant splicing outcome, e.g., in-frame exon 29 skipping,
cannot be excluded (Additional file 1: Figure S3). The
AN_002507 pediatric patient exhibited the three major
cEDS criteria, certain dysmorphisms and easy bruising
without other signs and complications. In contrast, her
mother (patient AN_002508) did not fulfill the majorcriteria and was diagnosed following the characterization
of her daughter (Table 1).
Lastly, in the AN_002512-13 family, a small genomic
deletion (c.2952+2_2952+3del) that involved the splice
donor site of exon 37 in the α1(V)-triple helix domain
was detected. This mutation was in silico predicted to
cause in-frame skipping of exon 37 [p.(Gly967_Thr984del)]
(Additional file 1: Figure S4). The activation of a cryptic
splice donor site within intron 37 cannot be excluded; in
this case, the mutation’s consequence would most likely be
frameshift and NMD. Patient AN_002513 showed a
complete phenotype, whereas his 41-year-old mother
(AN_002512) did not and was diagnosed following the
characterization of her son (Table 1).
The c.3413G>A (exon 43) and c.4178G>A (exon 54)
mutations were identified in the AN_002518-19 family
and in AN_002526, respectively. These are typical glycine
substitutions within the triple helix domain that result in
replacement of glycine with a bulkier amino acid [p.
(Gly1138Glu) and p.(Gly1393Asp)]. Patients AN_002518
and AN_002519 showed a complete phenotype;
AN_002526 was the most severely affected patient among
those carrying a COL5A1 mutation (Table 1).
In conclusion, considering all of the characterized pa-
tients with COL5A1 mutations, genotype-phenotype cor-
relations were not observed when comparing the
phenotypic severity of patients with a null allele and
those with structural mutations. One exception to this is
a possible correlation between a glycine substitution in
the C-terminus of the collagenous domain and a severe
phenotype, as was observed for patient AN_002526.
Furthermore, the structural mutation in the N-terminal
region of the pro-α1(V) collagen chain in patient
AN_002502 was associated with unusual ocular involve-
ment and a severe phenotype.
The two patients of our cohort with the most severe
phenotype were determined to carry COL5A2 defects. In
both of these patients, a structural mutation appeared de
novo and produced in-frame skipping of the affected
exon. Specifically, for patient AN_002533 (c.1977G>A),
a synonymous substitution in the codon for the proline
at position 659 was detected. This mutation alters the
consensus donor splice site and is predicted in silico to
cause the in-frame deletion of the 18 amino acids that are
encoded by exon 29 [p.(Gly642_Pro659del)] (Additional
file 1: Figure S5). The skipping of exon 29 was also re-
ported for the c.1947A>G transition within this exon,
abolishing an ESE consensus site [18]. The second
COL5A2 mRNA splice mutation was identified in pa-
tient AN_002534 and consisted of a c. 2499+2T>C tran-
sition, which affects the consensus donor splice site of
exon 37 and is predicted to cause in-frame exon skip-
ping (Additional file 1: Figure S6A). This prediction
was verified by performing RT-PCR of total RNA that
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analysis confirmed the in-frame skipping of exon 37
[p.(Gly816_Pro833del)] (Additional file 1: Figure S6B).
Discussion
cEDS is a rare multisystem disorder that is incompletely
understood at the clinical and molecular level. In this 3-
year work, we adopted a diagnostic strategy that was
based on a careful clinical evaluation of 40 patients
followed by a specific molecular analysis flowchart de-
veloped to simplify and expedite the diagnostic proced-
ure. The physical examination revealed high inter- and
intra-familial variability in cEDS, with phenotypes ran-
ging from severe to nearly undetectable. The molecular
analysis allowed for the identification of COL5A1/
COL5A2 defects in approximately 93% of the probands,
supporting the recent findings that these are the major,
if not the only, causal genes of cEDS [18].
The clinical diagnosis of cEDS was based on Ville-
franche nosology’s major and minor criteria, including
cutaneous involvement, i.e., skin hyperextensibility, de-
fective scarring, and articular hypermobility [1-6,18]. We
observed that skin hyperextensibility was present to a
varying degree, ranging from marked to poor or even
absent. Poorly hypextensible skin is often present in
hEDS patients, who exhibit a certain degree of clinical
overlap with cEDS, especially with those without marked
skin hyperextensibility [10]. Multiple abnormal scars
were observed in 95% of the patients. Only a small atro-
phic scar was present in two adult patients, and scars
were not detected in two patients. The absence of atro-
phic scars or the presence of atrophic post-surgical scars
is often observed in hEDS patients [10, our observations].
Therefore, the above mentioned patients, who also
presented articular involvement and minor signs that are
common to hEDS, had a phenotype that was compatible
with hEDS. The diagnosis of cEDS was reached based on
the existence of relatives who were clearly affected with
cEDS, i.e., fulfilling the three major criteria, and was con-
firmed using molecular genetics testing that identified the
causal mutations. The third major criterion of cEDS, i.e.,
joint hypermobility, was present in all but eight of the pa-
tients. These observations confirm that, in our cohort, the
three major Villefranche criteria are useful and sufficient
for a clinical diagnosis of cEDS in the large majority of pa-
tients [18]. These criteria are inadequate for a small num-
ber of subjects, but minor signs and family history can
suggest the presence of the disorder also in patients who
do not fulfill the three major criteria. In the absence of
family history, patients without clear skin involvement
and joint hypermobility are not easily diagnosed by physi-
cians and can even escape clinical observation; therefore,
the disorder is most likely under-recognized and is cer-
tainly underestimated. For all of the borderline patients, areliable genetic test can rapidly make a diagnosis or
suggest a diagnosis of hEDS or other connective tissue
disorders. Minor criteria affect, to varying degrees, the cu-
taneous, articular and musculoskeletal systems and in-
clude both dysmorphic and systemic signs. Such signs
support the clinical diagnosis and confirm generalized
connective tissue fragility/involvement. More specifically,
musculoskeletal involvement and articular chronic pain,
either localized or generalized, was observed in 60% of the
adult patients. Interestingly, none of these patients used
daily therapy, except for one patient who was treated with
FANS. The other patients required pain therapy with
FANS for sporadic events. The greater tolerance of articu-
lar pain and the different pain therapies distinguishes
cEDS from hEDS patients, with the latter in general
requiring daily treatment, often with opioid drugs [41].
Molecular analyses of COL5A1 and COL5A2 genes
detected defects in 26 of 28 cEDS probands (approxi-
mately 93%), adding 20 novel mutations to those that
have been previously reported. More than 60% of these
mutations arose de novo, and nearly all were private muta-
tions, except for two COL5A1 mutations that were identi-
fied twice in the present study and three COL5A1
mutations that were reported previously [18, and LOVD].
The majority of the causal mutations affected the
COL5A1 gene (90%), which is in agreement with the
data that are reported in the LOVD EDS variant database.
Similarly, approximately two-thirds of these COL5A1 mu-
tations were null allele mutations, comprising nonsense,
small del/ins, splice errors and a large duplication. All of
these mutations led to COLLV haploinsufficiency. Of
these, the most notable is the 191 kb duplication involving
the COL5A1 proximal promoter and the first 11 exons.
This case is the second gross genomic rearrangement that
has been described to affect this gene [20].
Only five structural mutations were identified in
COL5A1: two typical glycine substitutions in the triple
helix domain, two other unusual missense mutations, and
one in-frame exon skipping mutation. Of the unusual mis-
sense mutations, one was within the TSPN-1 domain of
the α1(V)-N-propeptide, and the second was at the X pos-
ition of the Gly-Xaa-Yaa motif, most likely resulting in
altered splicing. Among structural mutations, the most
notable is p.(Thr178Pro), which affects the TSPN-1 do-
main. This mutation is the first missense mutation that
has been identified in the α1(V)-N-propeptide and is
predicted to disturb both conformation and function,
with a dominant negative effect of perturbing collagen
fibrillogenesis and ECM organization. Indeed, the three
other reported mutations that affect the α1(V)-N-
propeptide are known to i) interfere with the formation
of COLLV heterotrimers and of the heterotypic fibrils
and ii) disturb the interactions between COLLV and
other ECM components, such as type VI collagen, TGF-
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[16,18,34,35].
Only two splice mutations were detected in COL5A2;
this low frequency and the type of mutation, i.e., in-
frame skipping of the affected exons with a dominant
negative effect, are in agreement with the data for this
gene deposited in the LOVD.
Lastly, the COL1A1 mutation p.(Arg312Cys), which is
known to be involved in the vascular-like cEDS [36], was
detected in one patient. Apart from the vascular involve-
ment, this patient did not show features different from
those observed in our cEDS patient’s cohort.
To date, no clear genotype-phenotype correlations have
been established for cEDS. This lack of correlations is hy-
pothesized to be related to the fact that COLLV is a minor
component of heterotypic fibrils that primarily contain
COLLI. This latter protein is much more abundant in the
ECM than COLLV and primarily has a structural support
function. In contrast, COLLV has a regulatory role in colla-
gen fibrillogenesis. It therefore was hypothesized that the
perturbation of this regulatory function, irrespective of the
nature of the COLLV mutation, is the principal determin-
ant of the functional and phenotypic outcome. This situ-
ation suggests a common pathogenic pathway for the
majority of COLLV mutations, in which the reduced avail-
ability of wild type COLLV is crucial. However, in certain
cases, other factors, such as increased ER stress and/or dis-
turbed interactions with other ECM molecules, could also
contribute to the phenotypic outcome [18,32-35]. In this
view, certain exceptions can be drawn for a subset of muta-
tions. Specifically, mutations with an atypical splicing out-
come in the N-terminal-propeptide domain of α1(V)
appear to be associated with a severe phenotype [18,34,35],
as do the two COL5A1 glycine substitutions [p.(Gly493Arg)
and p.(Gly1564Asp)] that were observed in patients with
cEDS with vascular complications [9,18]. The severe multi-
systemic phenotype with ocular involvement of the patient
with the mutation in the α1(V)-N-propeptide domain
strengthens the hypothesis that alterations in this domain
lead to severe clinical presentation. Interestingly, the
patient who was reported by Symoens et al. also
exhibited unusual eye involvement [35]. Furthermore,
given that, among the identified COL5A1 mutations,
the p.(Gly1393Asp) missense mutation at the C-
terminus of the collagenous domain was associated with
the most severe phenotype, we can speculate that the
rare COL5A1 glycine substitutions can also lead to a se-
vere phenotype, even without vascular complications. In
contrast, given that patients with mutations leading to
COL5A1 haploinsufficiency can also present with a se-
vere phenotype, even with arterial rupture, other genetic
and environmental factors likely modulate cEDS pheno-
types [4,8,18]. Although the number of clinically well-
described patients with cEDS and COL5A2 mutations islimited, the majority of them have severe phenotypes, as
in this study, and all of the COL5A2 mutations were
structural with a dominant negative effect [4,18,30,32].
This observation may therefore represent a consistent
genotype-phenotype correlation. Lastly, our patients and
their relatives who carried the COL1A1 p.(Arg312Cys) mu-
tation typically showed a cEDS phenotype with severe vas-
cular involvement and a propensity for arterial rupture in
young adulthood [36,38]. In general, genotype-phenotype
correlations are not evident in cEDS, and different genetic
backgrounds involving possible modulator genes and en-
vironmental factors likely contribute to the wide inter- and
intra-familial variability irrespective of the mutation type.
Although the number of patients who have been character-
ized at a clinical and molecular level is limited, certain ex-
ceptions still emerge that may be useful for genetic
counseling. The identical clinical presentation of the two
monozygotic twin sisters that were characterized in this
study support the above-mentioned role of modulator
genes and environment in cEDS clinical presentation.
Moreover, concerning intrafamilial variability, the most re-
markable phenotypic differences that we observed were in
two mothers and their children (families AN_002507-08
and AN_002512-13). These patients carried missense mu-
tations with a possible splice effect and a donor splice mu-
tation; we therefore speculate that these mutations can
lead to different intrafamilial outcomes due to the indi-
vidual set and efficiency of splicing factors that mature
the aberrant mRNAs, thus explaining the different clin-
ical severities. More specifically, in family AN_002507-
08, the p.(Glu812Asp) mutation can be a simple mis-
sense or could lead to the in-frame skipping of exon 29;
likewise, in family AN_002512-13, the detected donor
splice mutation may lead to structural in-frame skipping
of exon 37 or may activate a cryptic splice donor site
with consequent haploinsufficiency.
Here, we adopted a diagnostic cEDS flowchart that
was based principally on the clinical evaluation of the
patients and direct sequencing of the major genes that
are involved, COL5A1 and COL5A2. We began with
DNA that was purified from whole blood samples. To
date DNA sequencing has become a time-saving and
cost-effective approach compared to other techniques,
even including pre-screening methods, such as DHPLC
and HRM analyses. In addition to sequencing, we in-
cluded COL5A1 MLPA analysis to detect possible gross
rearrangements. Using this strategy, we failed to identify
the causal mutation for only two patients who had a
clear cEDS phenotype. Although additional genetic het-
erogeneity cannot be entirely excluded, the lack of iden-
tified mutations is most likely the result of technical
limitations of the sequencing method; for example, the
mutation detection strategy does not allow for the iden-
tification of deep intronic mutations, mutations in the
Ritelli et al. Orphanet Journal of Rare Diseases 2013, 8:58 Page 17 of 19
http://www.ojrd.com/content/8/1/58regulatory regions (promoter, 3’UTR, etc.), or large gen-
omic alterations in COL5A2. This limitation is because
MLPA analysis is unavailable for this gene and because
of rare private variants that fall within the primer
targeted sequences that could avoid PCR amplification
of the mutant allele.
Our molecular approach was selected to avoid the re-
quirement for a skin biopsy for diagnostic purposes. This
was done for the following reasons: i) biopsies are inva-
sive procedures that are not readily accepted by patients
with defective wound healing and for whom a clear clin-
ical diagnosis can be reached; ii) the establishment of
in vitro fibroblast cultures requires specific technical fa-
cilities and skills and is both costly and time-consuming;
iii) the identification of the causal mutation in the
COL5A1 gene beginning with cDNA is not possible for
null allele mutations, which represent the most frequent
alterations in this gene. The COL5A1 null allele test still
must be considered to be a valid approach for the evalu-
ation of the presence of a causal mutation; however, it
does not provide the type and position of the mutation,
which is detected by gDNA sequencing. The null allele
test may have been useful in the case of our two patients
without an identified causal mutation. Furthermore, skin
biopsy was not considered for COLLV biochemical ana-
lyses as it allows for the detection of abnormal protein
in only approximately 10% of patients [4,18].
Although our diagnostic strategy was very effective,
certain drawbacks remain. Primary among these was the
impossibility of examining the outcome of splice muta-
tions at the RNA level or the effect of given missense
mutations at the protein level. This problem is relevant
primarily for basic research and for understanding the
genotype-phenotype correlation; however, such informa-
tion is not useful to the diagnostic procedure. The iden-
tification of the causal mutation in patients with cEDS
remains a milestone with respect to the diagnostic iter
for these patients, especially for patients with unclear
clinical presentation. Moreover, the identification of
these mutations allows for effective genetic counseling,
follow-up and prenatal diagnosis.
In conclusion, this study indicates that the accurate
clinical evaluation of the patients and their relatives re-
duces the number of doubtful diagnoses. Using the flow-
chart here adopted, the patients without a clear suspect
of cEDS can be ascertained, and diagnoses can be con-
firmed by genetic testing, allowing for the identification
of the majority of the molecular defects.
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Additional file 1: Figure S1. In silico prediction of the effect of the
c.1165-2A>G splice acceptor mutation (intron 7, COL5A1) in the
AN_002503-05 patient’s family using four prediction programs (SpliceSite-
Finder-like, MaxEntScan, NNSPLICE and Human Splicing Finder) in Alamut
Software version 2.2. This mutation is predicted to cause the activation of
a cryptic splice acceptor site 4 bp downstream of the canonical site
inside exon 8, generating a frameshift and PTC formation [p.
(Pro389Leufs*168)]. Figure S2. In patient AN_002509, the de novo c.2647-
12A>G mutation in intron 31 of COL5A1 is predicted to create a new
splice acceptor site 11 bp upstream of the consensus acceptor site, with
the retention of the last 11 bases of intron 31 and a consequent
frameshift and PTC formation [p.(Gly883Leufs*195)]. Figure S3. In silico
analysis of the c.2436A>T mutation [p.(Glu812Asp)] in exon 29 of COL5A1
in the AN_002507-08 family suggests that this transversion alters exonic
splicing enhancer (ESE) sequences. The SF2/ASF binding site AAGACGG
has a decreased consensus score (3.1 vs. 1.98 by ESE-finder), and the
GTGAAG and GAAGAC consensus sites are abolished (Rescue_ESE).
Therefore, an aberrant splicing outcome, for example in-frame skipping of
exon 29, cannot be excluded. Figure S4. The small genomic deletion
(c.2952+2_2952+3del), which abolishes the splice donor site of exon 37
of COL5A1, was detected in the AN_002512-13 family and is predicted to
cause in-frame skipping of exon 37 p.(Gly967_Thr984del). Figure S5. The
COL5A2 transition c.1977G>A in patient AN_002533. This mutation is a
synonymous substitution in the codon of the proline at position 659 and
abolishes the consensus donor splice site. It is therefore predicted that
this mutation causes the in-frame deletion of the 18 amino acids that are
encoded by exon 29 p.(Gly642_Pro659del). Figure S6. A. The COL5A2
transition c.2499+2T>C in patient AN_002534 affects the consensus
donor splice site of exon 37 and is predicted to cause in-frame skipping
of exon 37. B. RT-PCR of the total RNA that was purified from patient
AN_002534’s skin fibroblasts using primers encompassing exons 36-38.
The results demonstrate that the c.2499+2T>C mutation leads to in-frame
exon 37 skipping [p.(Gly816_Pro833del)].
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